LAB

#3463
Standard BioTools Inc. - Common Stock
0.6 4 USD
-0.02%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
0.64
0.64
Jahresspanne
0.63
1.72
Tagesänderung
-1.54%
Monatliche Änderung
-27.27%
6 month change
-41.28%
Jahresänderung
-47.97%
Vorheriger Schlusskurs
0.6 5
Open
0.6 4
Tief
0.6 4
Hoch
0.6 4
Volumen
17
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
STANDARD BIOTOOLS INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
STANDARD BIOTOOLS INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
STANDARD BIOTOOLS INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
STANDARD BIOTOOLS INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
STANDARD BIOTOOLS INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
STANDARD BIOTOOLS INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
STANDARD BIOTOOLS INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
STANDARD BIOTOOLS INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
STANDARD BIOTOOLS INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
STANDARD BIOTOOLS INC. current report, Q2 FY2026
8-K

STANDARD BIOTOOLS INC. current report, Q3 FY2024

Full document

Standard BioTools Inc. 8-K Summary

Business Context and Reporting Period

This Form 8-K Current Report was filed by Standard BioTools Inc. on July 31, 2024, covering events occurring on July 26, 2024, and July 30, 2024. The Company is incorporated in Delaware and trades on the Nasdaq Global Select Market under the symbol "LAB".

Key Financial Metrics

This filing is a current report regarding corporate governance and personnel changes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.

Material Changes

  • Executive Departure: Jeffrey Black resigned as Senior Vice President and Chief Financial Officer, effective August 31, 2024. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices, but rather to accept an opportunity at another public company.
  • Interim Appointment: The Board of Directors appointed Alex Kim, currently the Chief Operating Officer, to serve as Interim Chief Financial Officer starting September 1, 2024. Mr. Kim will continue to serve as Chief Operating Officer concurrently.

Guidance, Outlook, and Risks

The Company has initiated a search process to identify a permanent successor for the Chief Financial Officer role. There are no family relationships between Mr. Kim and any director or executive officer requiring disclosure, and no reportable transactions or arrangements were disclosed regarding his appointment. No financial guidance, outlook, or specific risk factors were detailed in this specific filing.

Investor Verification Checklist

  • Verify the effective date of the CFO transition (August 31, 2024) and the start date of the Interim CFO (September 1, 2024).
  • Confirm the status of the search for a permanent Chief Financial Officer.
  • Review the Company's most recent 10-Q or 10-K for financial performance data, as this 8-K contains no financial results.
  • Check for any subsequent press releases regarding the permanent CFO appointment.

Nachrichten